Loading
Showed that counting tumour cells in blood predicts survival in breast cancer and co-led PALOMA-3, which brought palbociclib to endocrine-resistant disease.
Massimo Cristofanilli (Weill Cornell Medicine, New York) led the 2004 study showing that circulating tumour cell counts predict survival in metastatic breast cancer, the founding clinical result for liquid biopsy. He was co-principal investigator of PALOMA-3, which established palbociclib plus fulvestrant after endocrine progression, and has led inflammatory breast cancer programmes. His work now focuses on ctDNA and CTC-guided treatment.
Shares Inflammatory breast cancer, CDK4/6, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag breast.
Shares CDK4/6, Estrogen receptor (ERα), CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag breast.
Shares CDK4/6, Palbociclib, CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer and the tag breast.
Shares Palbociclib, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Inflammatory breast cancer, CDK4/6, Palbociclib, CDK4/6 inhibitors and the tag breast.
Shares Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer and the tag breast.
Shares Inflammatory breast cancer, Liquid biopsy (ctDNA), HR-positive / HER2-negative breast cancer and the tag breast.